Gary J. Doherty

6.9k total citations · 1 hit paper
44 papers, 4.2k citations indexed

About

Gary J. Doherty is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Gary J. Doherty has authored 44 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 15 papers in Pulmonary and Respiratory Medicine and 14 papers in Oncology. Recurrent topics in Gary J. Doherty's work include Cancer Genomics and Diagnostics (8 papers), Cellular transport and secretion (7 papers) and Lung Cancer Treatments and Mutations (6 papers). Gary J. Doherty is often cited by papers focused on Cancer Genomics and Diagnostics (8 papers), Cellular transport and secretion (7 papers) and Lung Cancer Treatments and Mutations (6 papers). Gary J. Doherty collaborates with scholars based in United Kingdom, United States and Japan. Gary J. Doherty's co-authors include Harvey T. McMahon, Daniel Muñoz‐Espín, Marta Pàez‐Ribes, Estela González‐Gualda, Richard Lundmark, Claire M. Connell, Pippa Corrie, Yvonne Vallis, Margaret A. Tempero and Cristina González‐López and has published in prestigious journals such as Journal of Clinical Oncology, Genes & Development and Annual Review of Biochemistry.

In The Last Decade

Gary J. Doherty

42 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mechanisms of Endocytosis

2009 2.3k citations Gary J. Doherty, Harvey T. McMahon profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gary J. Doherty United Kingdom	19	2.3k	1.1k	658	637	471	44	4.2k
Roberto Weigert United States	38	2.9k 1.3×	1.9k 1.7×	572 0.9×	499 0.8×	817 1.7×	106	5.7k
Radu V. Stan United States	36	4.1k 1.8×	2.4k 2.1×	970 1.5×	406 0.6×	727 1.5×	58	6.3k
Philmo Oh United States	19	2.3k 1.0×	1.2k 1.1×	675 1.0×	590 0.9×	385 0.8×	26	3.8k
Jacky G. Goetz France	34	2.6k 1.2×	1.8k 1.6×	330 0.5×	946 1.5×	627 1.3×	90	4.8k
Yosuke Hashimoto Japan	35	2.4k 1.0×	1.0k 0.9×	325 0.5×	976 1.5×	791 1.7×	195	4.8k
Jonas Emsley United Kingdom	38	2.0k 0.9×	944 0.8×	200 0.3×	289 0.5×	953 2.0×	108	5.6k
Bharat Joshi United States	42	2.8k 1.2×	847 0.7×	468 0.7×	1.1k 1.7×	1.6k 3.5×	109	5.5k
Casey Cunningham United States	33	2.2k 1.0×	1.1k 1.0×	256 0.4×	1.4k 2.2×	646 1.4×	87	4.4k
Andrius Masedunskas United States	24	1.2k 0.5×	648 0.6×	319 0.5×	275 0.4×	384 0.8×	56	2.9k
John Yu United States	43	4.4k 1.9×	802 0.7×	1.2k 1.9×	879 1.4×	704 1.5×	161	6.9k

Countries citing papers authored by Gary J. Doherty

Since Specialization

Citations

This map shows the geographic impact of Gary J. Doherty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary J. Doherty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary J. Doherty more than expected).

Fields of papers citing papers by Gary J. Doherty

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary J. Doherty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary J. Doherty. The network helps show where Gary J. Doherty may publish in the future.

Co-authorship network of co-authors of Gary J. Doherty

This figure shows the co-authorship network connecting the top 25 collaborators of Gary J. Doherty. A scholar is included among the top collaborators of Gary J. Doherty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary J. Doherty. Gary J. Doherty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kurland, John F., Gary J. Doherty, Stephan Hois, et al.. (2025). Differential safety profiles of durvalumab monotherapy and durvalumab in combination with tremelimumab in adult patients with advanced cancers. Journal for ImmunoTherapy of Cancer. 13(5). e011140–e011140.

Cheng, Vinton W.T., Rasheed Zakaria, Amanda Fitzpatrick, et al.. (2024). BMScope: A scoping review to chart the evolving clinical study landscape in brain and leptomeningeal metastasis. Neuro-Oncology. 26(12). 2193–2207. 1 indexed citations

Abbosh, Chris, Darren Hodgson, Gary J. Doherty, et al.. (2024). Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer. Trends in cancer. 10(7). 643–654. 18 indexed citations

Reck, Martin, Davina Gale, Zhou Zhu, et al.. (2024). LBA49 Associations of ctDNA clearance (CL) during neoadjuvant Tx with pathological response and event-free survival (EFS) in pts with resectable NSCLC (R-NSCLC): Expanded analyses from AEGEAN. Annals of Oncology. 35. S1239–S1239. 15 indexed citations

Heymach, John V., David Harpole, Janis M. Taube, et al.. (2024). OA13.03 Perioperative Durvalumab for Resectable NSCLC (R-NSCLC): Updated Outcomes from the Phase 3 AEGEAN Trial. Journal of Thoracic Oncology. 19(10). S38–S39. 5 indexed citations

Heymach, John V., David H. Harpole, Tetsuya Mitsudomi, et al.. (2023). Abstract CT005: AEGEAN: A phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC. Cancer Research. 83(8_Supplement). CT005–CT005. 55 indexed citations

Reck, Martin, Daniel P. Gale, David H. Harpole, et al.. (2023). LBA59 Associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase III AEGEAN trial. Annals of Oncology. 34. S1300–S1300. 23 indexed citations

Pugh, Trevor J., Jeffrey P. Bruce, Gary J. Doherty, et al.. (2022). AACR Project GENIE: 100,000 Cases and Beyond. Cancer Discovery. 12(9). 2044–2057. 49 indexed citations

Navani, Neal, et al.. (2022). Optimising tissue acquisition and the molecular testing pathway for patients with non-small cell lung cancer: A UK expert consensus statement. Lung Cancer. 172. 142–153. 10 indexed citations

10.

Thompson, Nicola, Grant D. Stewart, Sarah J. Welsh, et al.. (2022). The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy. BMC Cancer. 22(1). 99–99. 18 indexed citations

11.

Hubank, Michael, et al.. (2021). Response of NOTCH1-Activated Tracheal Adenoid Cystic Carcinoma to the Gamma Secretase Inhibitor Nirogacestat. JCO Precision Oncology. 5(5). 1579–1583. 4 indexed citations

12.

Venkatesh, Ashwin, Kieren Allinson, Tilak Das, et al.. (2021). Response to BRAF and MEK1/2 inhibition in a young adult with BRAF V600E mutant epithelioid glioblastoma multiforme: A Case Report and Literature Review. Current Problems in Cancer. 45(5). 100701–100701. 7 indexed citations

13.

Doherty, Gary J., et al.. (2020). Rethinking cancer clinical trials for COVID-19 and beyond. Nature Cancer. 1(6). 568–572. 27 indexed citations

14.

Doherty, Gary J., et al.. (2020). Recommendations from national regulatory agencies for ongoing cancer trials during the COVID-19 pandemic. The Lancet Oncology. 21(5). 624–627. 17 indexed citations

15.

Turrell, Frances K., Emma Kerr, Meiling Gao, et al.. (2017). Lung tumors with distinct p53 mutations respond similarly to p53 targeted therapy but exhibit genotype-specific statin sensitivity. Genes & Development. 31(13). 1339–1353. 56 indexed citations

16.

Connell, Claire M. & Gary J. Doherty. (2017). Activating HER2 mutations as emerging targets in multiple solid cancers. ESMO Open. 2(5). e000279–e000279. 110 indexed citations

17.

Doherty, Gary J., Adam Duckworth, Susan Davies, et al.. (2017). Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury. ESMO Open. 2(4). e000268–e000268. 96 indexed citations

18.

Sánchez-Barrena, María José, Yvonne Vallis, Menna R. Clatworthy, et al.. (2012). Bin2 Is a Membrane Sculpting N-BAR Protein That Influences Leucocyte Podosomes, Motility and Phagocytosis. PLoS ONE. 7(12). e52401–e52401. 37 indexed citations

19.

Doherty, Gary J., Mark T. Howes, Björn Morén, et al.. (2011). The endocytic protein GRAF1 is directed to cell-matrix adhesion sites and regulates cell spreading. Molecular Biology of the Cell. 22(22). 4380–4389. 44 indexed citations

20.

Hope, AB, et al.. (1985). Proton Motive Force and Phosphorylation Potential in Thylakoids. Australian Journal of Plant Physiology. 12(1). 21–26. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact